Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

Publication ,  Journal Article
Verstovsek, S; Mesa, RA; Gotlib, J; Levy, RS; Gupta, V; DiPersio, JF; Catalano, JV; Deininger, M; Miller, C; Silver, RT; Talpaz, M; Winton, EF ...
Published in: N Engl J Med
March 1, 2012

BACKGROUND: Ruxolitinib, a selective inhibitor of Janus kinase (JAK) 1 and 2, has clinically significant activity in myelofibrosis. METHODS: In this double-blind trial, we randomly assigned patients with intermediate-2 or high-risk myelofibrosis to twice-daily oral ruxolitinib (155 patients) or placebo (154 patients). The primary end point was the proportion of patients with a reduction in spleen volume of 35% or more at 24 weeks, assessed by means of magnetic resonance imaging. Secondary end points included the durability of response, changes in symptom burden (assessed by the total symptom score), and overall survival. RESULTS: The primary end point was reached in 41.9% of patients in the ruxolitinib group as compared with 0.7% in the placebo group (P<0.001). A reduction in spleen volume was maintained in patients who received ruxolitinib; 67.0% of the patients with a response had the response for 48 weeks or more. There was an improvement of 50% or more in the total symptom score at 24 weeks in 45.9% of patients who received ruxolitinib as compared with 5.3% of patients who received placebo (P<0.001). Thirteen deaths occurred in the ruxolitinib group as compared with 24 deaths in the placebo group (hazard ratio, 0.50; 95% confidence interval, 0.25 to 0.98; P=0.04). The rate of discontinuation of the study drug because of adverse events was 11.0% in the ruxolitinib group and 10.6% in the placebo group. Among patients who received ruxolitinib, anemia and thrombocytopenia were the most common adverse events, but they rarely led to discontinuation of the drug (in one patient for each event). Two patients had transformation to acute myeloid leukemia; both were in the ruxolitinib group. CONCLUSIONS: Ruxolitinib, as compared with placebo, provided significant clinical benefits in patients with myelofibrosis by reducing spleen size, ameliorating debilitating myelofibrosis-related symptoms, and improving overall survival. These benefits came at the cost of more frequent anemia and thrombocytopenia in the early part of the treatment period. (Funded by Incyte; COMFORT-I ClinicalTrials.gov number, NCT00952289.).

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

N Engl J Med

DOI

EISSN

1533-4406

Publication Date

March 1, 2012

Volume

366

Issue

9

Start / End Page

799 / 807

Location

United States

Related Subject Headings

  • Splenomegaly
  • Spleen
  • Quality of Life
  • Pyrimidines
  • Pyrazoles
  • Protein Kinase Inhibitors
  • Primary Myelofibrosis
  • Organ Size
  • Nitriles
  • Middle Aged
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., … Kantarjian, H. M. (2012). A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med, 366(9), 799–807. https://doi.org/10.1056/NEJMoa1110557
Verstovsek, Srdan, Ruben A. Mesa, Jason Gotlib, Richard S. Levy, Vikas Gupta, John F. DiPersio, John V. Catalano, et al. “A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.N Engl J Med 366, no. 9 (March 1, 2012): 799–807. https://doi.org/10.1056/NEJMoa1110557.
Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012 Mar 1;366(9):799–807.
Verstovsek, Srdan, et al. “A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.N Engl J Med, vol. 366, no. 9, Mar. 2012, pp. 799–807. Pubmed, doi:10.1056/NEJMoa1110557.
Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012 Mar 1;366(9):799–807.

Published In

N Engl J Med

DOI

EISSN

1533-4406

Publication Date

March 1, 2012

Volume

366

Issue

9

Start / End Page

799 / 807

Location

United States

Related Subject Headings

  • Splenomegaly
  • Spleen
  • Quality of Life
  • Pyrimidines
  • Pyrazoles
  • Protein Kinase Inhibitors
  • Primary Myelofibrosis
  • Organ Size
  • Nitriles
  • Middle Aged